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Summary
Kidney transplant recipients receiving calcineurin inhibitor-based immunosup-
pression incur increased long-term risks of cancer and kidney fibrosis. Switch to
mammalian target of rapamycin (mTOR) inhibitors may reduce these risks. Ste-
roid or Cyclosporin Removal After Transplant using Everolimus (SOCRATES), a
36-month, prospective, multinational, open-label, randomized controlled trial for
de novo kidney transplant recipients, assessed whether everolimus switch could
enable elimination of mycophenolate plus either steroids or CNI without com-
promising efficacy. Patients received cyclosporin, mycophenolate and steroids for
the first 14 days then everolimus with mycophenolate and CNIwithdrawal (CNI-
WD); everolimus with mycophenolate and steroid withdrawal (steroid-WD); or
cyclosporin, mycophenolate and steroids (control). 126 patients were random-
ized. The steroid WD arm was terminated prematurely because of excess discon-
tinuations. Mean eGFR at month 12 for CNI-WD versus control was 65.1 ml/
min/1.73 m2 vs. 67.1 ml/min/1.73 m2 by ITT, which met predefined noninferior-
ity criteria (P = 0.026). The CNI-WD group experienced a higher rate of BPAR
(31% vs. control 13%, P = 0.048) and showed a trend towards higher composite
treatment failure (BPAR, graft loss, death, loss to follow-up). The 12 month
results from SOCRATES show noninferiority in eGFR, but a significant excess of
acute rejection when everolimus was commenced at week 2 to enable a
progressive withdrawal of mycophenolate and cyclosporin in kidney transplant
recipients.
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Introduction
A regimen containing calcineurin inhibitors, mycophenolic
acid and steroids is the cornerstone of modern immuno-
suppressive therapy for kidney transplant recipients, yield-
ing low rates of acute rejection and excellent short- to
medium-term graft survival [1–3]. However, longer-term
adverse effects on graft and patient contribute to premature
graft loss because of interstitial fibrosis and tubular atrophy
[4] and premature death due to cardiovascular disease [5]
or cancer [6].
Calcineurin inhibitors (CNI) are associated with short-
and long-term toxicities including acute and chronic
nephrotoxicity [7] and development or exacerbation of
cardiovascular risk factors including diabetes in particular
[1,8]. Mycophenolic acid (MPA) is associated with bone
marrow toxicity and gastrointestinal intolerance [9]. Oral
corticosteroids incur well-documented complications includ-
ing osteoporosis, diabetes and cardiovascular disease [10].
Everolimus is a mammalian target of rapamycin inhibi-
tor (mTORi) that is a macrocyclic lactone with immuno-
suppressive as well as antimalignant properties [11].
mTORis, when used in combination with full-dose CNI,
have been shown to exacerbate CNI nephrotoxicity [12].
Trials have demonstrated the beneficial effects of CNI with-
drawal for selected patients receiving mTORis in terms of
improved renal function [13,14], although data to demon-
strate that such improvement leads to improved graft sur-
vival are awaited. Conversion from CNI- to mTORi-based
therapy for kidney transplant recipients with a past history
of nonmelanoma skin cancer has recently been shown to
reduce recurrence and development of new skin cancers
[15,16]. Definitive data on the impact of mTORi on other
post-transplant malignancies are awaited.
The Steroid or Cyclosporin Removal After Transplant
using Everolimus (SOCRATES) study was designed to
assess whether the use of everolimus could enable the elimi-
nation of mycophenolate plus either steroids or CNI with-
out compromising efficacy, in a bid to reduce the morbidity
associated with long-term usage of the other molecules.
We present the 12 month results which assessed whether
everolimus and steroids or everolimus and reduced dose
CsA are able to provide noninferior efficacy and safety
compared with cyclosporin (CsA), MPA and steroids, but
are able to minimize long-term kidney, cardiovascular and
metabolic risks.
Materials and methods
The SOCRATES study is a 36-month, prospective, multina-
tional, open-label, randomized, controlled trial which was
designed by the authors and sponsored by Novartis. The
study was conducted across 11 centres, in Australia (five
centres), Korea (two centres), Malaysia (one centre), New
Zealand (one centre) and Taiwan (two centres).
De novo kidney transplant recipients aged 18–65 were eli-
gible. Key exclusions were recipients of multi-organ, ABO-
incompatible or T cell cross-match positive grafts, peak
PRA >50% or loss of a previous allograft within 6 months
of transplantation due to acute rejection.
After provision of written informed consent, patients
were enrolled and randomized to a treatment on the day of
transplantation. Basiliximab 20 mg (Simulect, Novartis)
was initially only given for delayed graft function, but after
a protocol amendment in July 2008, it was given according
to local centre practice. For the first 14 days, all patients
received cyclosporin microemulsion (CsA, Neoral, Novar-
tis) adjusted to achieve a C2 target of 1500 ng/ml, myco-
phenolate sodium (MPA, Myfortic, Novartis) 720 mg bd
and corticosteroids.
From day 15 to 60, different treatment allocations were
started. Subjects in the CNI withdrawal (CNI-WD) and
corticosteroid withdrawal (steroid-WD) groups were com-
menced on everolimus (to achieve a trough concentration
of 6–10 ng/ml), CsA was reduced by 50%, steroids were
continued, and MPA was discontinued once the everolimus
trough concentration exceeded 6 ng/ml. The control group
was continued on CsA, MPA and steroids for the duration
of the trial.
From day 61 to 120, the CNI-WD group had the everoli-
mus dose increased, to achieve a trough level of 8–12 ng/ml,
steroids were continued, and CsA was discontinued. The
steroid-WD group continued on everolimus to achieve a
trough level of 6–10 ng/ml, continued on CsA at a reduced
dose of 50% and had gradual withdrawal of prednisone by
1 mg/week to be discontinued by day 120 (Fig. 1).
The study was designed and implemented in accordance
with the ICH Harmonized Tripartite Guidelines for Good
Clinical Practice, with applicable local regulations and with
the ethical principles laid down in the Declaration of
Helsinki.
SOCRATES was registered on ClinicalTrials.gov and
identified by the code NCT00371826.
Endpoints
The primary endpoint was difference in kidney function
(eGFR using the Nankivell method) at 12 months after kid-
ney transplantation. The main secondary endpoints were the
incidence of biopsy-proven acute rejection (BPAR), graft sur-
vival, death and loss to follow-up and a composite of these.
Sample size
The everolimus and control groups were assumed to both
have eGFR 60  17 ml/min/1.73 m2 at month 12. To
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control for multiple comparisons, the one-sided signifi-
cance level was set at 0.025. A noninferiority margin was set
at 9 ml/min/1.73 m2 and measured by two independent
sample t-test based on a 95% CI. A sample size of 51
patients per arm would have 75% power to show that the
12-month mean GFR value of the everolimus arm is not
worse than the control arm by 9 ml/min/1.73 m2 or more.
A total sample size of 177 patients (59 patients per group)
was chosen to allow for a 15% dropout rate.
Randomization and blinding
Randomization was performed by Novartis drug supply
management and was subjected to quality control proce-
dures by the Novartis biostatistics quality assurance group.
The investigator received a set of treatment allocation cards
with sequential randomization numbers on which the treat-
ment group information was covered by a scratch-off label.
Treatment allocation cards were used to avoid bias in
assignment of the patients to groups in the specified 1:1:1
ratio. Following enrolment, the investigator removed the
scratch-off label from the numbered treatment allocation
card to reveal the allocated treatment group.
The investigators and patients were not blinded in this
open-label study.
Statistical methods
Difference in graft function (eGFR, Nankivell method) was
used as the primary efficacy criterion to demonstrate that
either of the CNI-WD or steroid-WD groups were not infe-
rior to control group by 9 ml/min/1.73 m2 or more. Type I
error probability was set at 0.05, one-sided. All other
efficacy and safety variables are presented by descriptive
statistics and were compared between both treatments
using appropriate tests for unpaired or paired (laboratory
data and vital signs) observations. Categorical variables
were analysed with the chi-squared test or Fisher’s exact
test. Time to event data including rates of affected patients
was assessed by Kaplan–Meier statistics and compared
between the two groups with the log-rank test.
A case report form (CRF) error failed to record month
12 eGFR for patients who prematurely discontinued the
study medication. This flaw was not discovered until after
database lock and resulted in sites being retrospectively
asked to provide the missing data. The database underwent
unlock/relock to include this data. All results presented
include this data and were analysed according to the pro-
spectively planned statistical approach using intention-
to-treat groups.
Results
A total of 133 patients were screened for enrolment,
between March 2006 and July 2010, of whom 126 were ran-
domized and thereby provided data for this 12-month
analysis (CNI-WD n = 49, steroid-WD n = 30, control
n = 47). One patient was not treated as randomized, being
treated with the control regimen rather than CNI-WD.
Baseline demographic characteristics are summarized in
Table 1. The three groups were generally comparable with
respect to transplant recipient demographic and back-
ground characteristics (Table 1). The majority of patients
were Caucasian (50.8%), were undergoing their first trans-
plantation and had more than two human leucocyte anti-
gen mismatches. There was a trend towards a higher
proportion of deceased donors in the CNI-WD group and
more living-related donors in the control group.
Figure 1 Study design. *Basiliximab induction allowed as of July 2008 by protocol amendment; EC-MPS: Myfortic; CNI + CsA: Neoral; Tx: transplant;
BSL: baseline.
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The steroid-WD arm was terminated early by the spon-
sor on the recommendation of the Data Monitoring Com-
mittee in March 2008 due to a higher premature treatment
discontinuation rate between this and the other two groups
which rendered continuation of this arm futile. Discontinu-
ations were mostly due to acute rejection, unsatisfactory
therapeutic effect and adverse events. The most common
reason for discontinuation of study medication from the
remaining groups was adverse events [CNI-WD n = 15
(30.6%), control n = 4 (8.5%)] (Fig. 2).










Recipient age in years (SD)
Mean 48.4 (10.17) 45.8 (10.83) 43.5 (10.66) 46.3 (10.63)
Range 24–65 20–64 23–62 20–65
Gender, n (%)
Male 32 (65.3) 34 (72.3) 24 (80.0) 90 (71.4)
Female 17 (34.7) 13 (27.7) 6 (20.0) 36 (28.6)
Race, n (%)
Caucasian 26 (53.1) 25 (53.2) 13 (43.3) 64 (50.8)
Black 0 (0.0) 0 (0.0) 1 (3.3) 1 (0.8)
Asian 19 (38.8) 19 (40.4) 14 (46.7) 52 (41.3)
Pacific Islander 0 (0.0) 3 (6.4) 1 (3.3) 4 (3.2)
Other 4 (8.2) 0 (0.0) 1 (3.3) 5 (4.0)
Body Mass Index in kg/m2 (SD)
Mean 25.1 (4.45) 25.0 (3.88) 26.2 (3.86) 25.3 (4.11)
Range 16.5–34.4 17.4–32.0 20.5–35.1 16.5–35.1
End-stage disease leading to transplantation, n (%)
Glomerular disease 24 (49.0) 17 (36.2) 10 (33.3) 51 (40.5)
Pyelonephritis 0 (0.0) 1 (2.1) 0 (0.0) 1 (0.8)
Polycystic disease 5 (10.2) 9 (19.1) 1 (3.3) 15 (11.9)
Hypertension/nephrosclerosis 1 (2.0) 4 (8.5) 6 (20.0) 11 (8.7)
Drug-induced toxicity 1 (2.0) 0 (0.0) 0 (0.0) 1 (0.8)
Diabetes mellitus 3 (6.1) 2 (4.3) 1 (3.3) 6 (4.8)
Interstitial nephritis 0 (0.0) 2 (4.3) 0 (0.0) 2 (1.6)
Vasculitis 0 (0.0) 0 (0.0) 1 (3.3) 1 (0.8)
Obstructive disorder/reflux 2 (4.1) 2 (4.3) 1 (3.3) 5 (4.0)
Unknown origin 10 (20.4) 9 (19.1) 7 (23.3) 26 (20.6)
Other 3 (6.1) 1 (2.1) 3 (10.0) 7 (5.6)
Number of HLA mismatches, n (%)
None 3 (6.1) 6 (12.8) 2 (6.7) 11 (8.7)
One 8 (16.3) 5 (10.6) 0 (0.0) 13 (10.3)
Two 9 (18.4) 6 (12.8) 3 (10.0) 18 (14.3)
>two 27 (55.1) 27 (57.4) 24 (80.0) 78 (61.9)
Missing 2 (4.1) 3 (6.4) 1 (3.3) 6 (4.8)
Number of previous renal transplantations, n (%)
None 47 (95.9) 46 (97.9) 30 (100.0) 123 (97.6)
One transplantation 1 (2.0) 1 (2.1) 0 (0.0) 2 (1.6)
Missing 1 (2.0) 0 (0.0) 0 (0.0) 1 (0.8)
Cold ischaemia time in hours (SD)
Mean 6.2 (4.90) 5.2 (4.60) 7.3 (6.87) 6.1 (5.35)
Range 0.1–16.0 0.3–20.0 0.1–24.5 0.1–24.5
Donor age in years (SD)
Mean 48.6 (12.60) 40.8 (13.13) 48.1 (13.66) 45.5 (13.47)
Range 16–70 9–71 23–71 9–71
Donor characteristics, n (%)
Cadaveric heart beating 20 (40.8) 15 (31.9) 13 (43.3) 48 (38.1)
Cadaveric nonheart beating 2 (4.1) 1 (2.1) 1 (3.3) 4 (3.2)
Living related 17 (34.7) 22 (46.8) 12 (40.0) 51 (40.5)
Living unrelated 10 (20.4) 9 (19.1) 4 (13.3) 23 (18.3)
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Mean exposure to study medication was generally within
the protocol-define target ranges. Mean  SD everolimus
concentration in the CNI-WD group was 6.6  4.1 ng/ml
at month 6 and 6.7  2.6 ng/ml at month 12. Control
group patients achieved mean  SD cyclosporin C2
concentrations of 866  307 ng/ml at month 6 and
664  287 ng/ml at month 12, and received a mean  SD
daily dose of Myfortic of 1260  295 mg at month 12. Use
of basiliximab as induction therapy was balanced among the
CNI-WD (n = 28, 57%) and control (n = 25, 53%) groups.
Primary and secondary outcomes
Renal function
The difference in mean eGFR at month 12 between CNI-
WD [65.1 (SD 15.4) ml/min/1.73 m2] and control [67.1
(SD 18.2) ml/min/1.73 m2] groups was 2.4 ml/min/
1.73 m2 in the ITT population (Fig. 3). Difference in renal
function between CNI-WD and control groups met nonin-
feriority criteria (P = 0.026, 95% confidence interval 6.5
to 8.7). At week 2, the time at which everolimus was com-
menced by the CNI-WD group, eGFR was higher in the
control group than CNI-WD [controls 64.7 (SD20.0) vs.
CNI-WD 53.2 (SD20.1) ml/min/1.73 m2, P = 0.007]
(Fig. 3). When month 12 renal function was re-analysed by
Patient Flow
25 completed study medication
24 discontinued
15 adverse events
1 abnormal test procedure result(s) 
6  unsatisfactory therapeutic effect 
1 administrative problems
1 other
47 completed study phase
2 withdrew consent
49 assigned to CNI & MPS Withdrawal
(48 given everolimus + steroids–1 patient treated  
with CsA + MPS + steroids by investigator)
47 assigned to  Control
39 completed study medication
8 discontinued
4 adverse events
3 unsatisfactory therapeutic effect 
1 other
45 completed study phase
1 lost to follow-up
1 death
133 patients enrolled and assessed for eligibility 7 patients screening failure
2 unacceptable test procedure result(s)
2 unacceptable past medical history/
concomitant  diagnosis   
1 withdrew consent
2 unacceptable laboratory value (s)  126 randomly assigned  Day 1 after transplantation
30 assigned to  Steroid & MPS Withdrawal
6 completed study medication
24 discontinued
9 adverse events
1 abnormal test procedure result(s)     




22 completed study phase
5 withdrew consent
2 lost to follow-up
1 protocol violation
Figure 2 Trial profile.
Figure 3 Improvement in eGFR from time of randomization (week 2)
to month 12: box plot of CNI withdrawal and control groups by inten-
tion to treat, showing median (line), interquartile range (box), minimum
and maximum values (whiskers). Improvement in eGFR was not differ-
ent between the groups: 12.8 (SD18.8) vs. 5.3 (SD19.4) ml/min/
1.72 m2 for CNI withdrawal versus control, P = 0.089.
306 © 2013 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT 27 (2014) 302–311
The SOCRATES study Chadban et al.
ANCOVA (with week 2 eGFR results as a covariate), the
statistical noninferiority was P = 0.007. Indeed, the change
in mean eGFR from week 2 to month 12 was +12.8 (SD
18.8) ml/min/1.73 m2 for CNI-WD and +5.3 (SD 19.4)
ml/min/1.73 m2 for control (P = 0.089) (Fig. 3). Per-pro-
tocol analysis of improvement in renal function demon-
strated a significant benefit in favour of the CNI-WD
group of 17.5 ml/min/1.73 m2 vs. 5.7 ml/min/1.73 m2
(P = 0.03).
A higher proportion of the CNI-WD group received
deceased donor grafts. To exclude any confounding effect
of delayed graft function on change in eGFR between week
2 and month 12, we performed a sensitivity analysis
restricted to recipients of live donor grafts. Improvement
from week 2 to month 12 (59.8  12.8 vs. 72.6  11.6,
P = 0.012) was evident in the CNI-WD group, but not in
controls (68.1  17.9 vs. 67.3  19.0, P = 0.87).
Composite treatment failure
The CNI-WD group showed a trend towards higher rates
of the composite treatment failure endpoint (BPAR, graft
loss, death or loss to follow-up) with 16 patients versus 12
patients in the control group (P = 0.100). The control
group experienced one death which was due to sepsis on
day 89 and two graft losses (renal vein thrombosis on day
10 and acute rejection on day 156). The CNI-WD and
steroid-WD groups had no deaths or graft losses. The
majority of the efficacy failures were due to BPAR with a
significant excess seen in the CNI-WD group 15 (30.6%)
versus 6 (12.8%) in the control group (P = 0.048) (Table 2,
Fig. 4). Of those patients in the CNI-WD group who suf-
fered BPAR, four cases occurred prior to commencement
of everolimus and of the remaining 11 cases, all had ceased
mycophenolate and three of these patients also had sub-
therapeutic everolimus levels according to protocol. Seven
of CNI-WD and four of control patients who experienced
BPAR had not received basiliximab which represents 47%
vs. 67% of the total BPAR proportions of each group or
33% and 18% of patients in each group not exposed to
basiliximab, respectively.
Post hoc analysis of eGFR in patients with BPAR at
month 12 did not show major differences between groups,
with mean eGFR of 56.2 (SD 11.0) ml/min/1.73 m2 in
CNI-WD vs. 53.0 (SD 25.9) ml/min/1.73 m2 in the control
group.
Adverse events
The incidence of adverse events (AE) was similar across all
groups and are summarized in Table 3. Gastrointestinal
disorders were the most frequently reported (CNI-WD
group 45 patients (92%), control group 40 (85%), steroid-
WD group 22 (73%), with diarrhoea being the most com-
mon symptom. The incidence of serious adverse events was
similar between the CNI-WD (67%) and control (66%)
groups. Wound healing events were similar (33% in the
CNI-WD, 32% in control and 30% in the steroid-WD
group). The reported incidence of skin cancer was low
[two patients in CNI-WD (4%) and one (2%) control]
and there were no nonskin malignancies reported for
any group. More adverse events led to permanent
















BPAR 15 (30.6) 6 (12.8) 5 (16.7) 0.0479
Banff type IA 7 (14.3) 3 (6.4) 5 (16.7) 0.3179
Banff type IB 5 (10.2) 4 (8.5) 0 (0.0) 1.0000
Banff type IIA 6 (12.2) 0 (0.0) 0 (0.0) 0.0267
Banff type IIB 1 (2.0) 1 (2.1) 0 (0.0) 1.0000
Banff type III 0 (0.0) 1 (2.1) 0 (0.0) 0.4896
Banff type
unspecified
1 (2.0) 1 (2.1) 0 (0.0) 1.0000
Graft loss 0 (0.0) 2 (4.3) 0 (0.0) 0.2371
Death 0 (0.0) 1 (2.1) 0 (0.0) 0.4896
Loss to follow-up 1 (2.0) 0 (0.0) 6 (20.0) 1.0000
Treatment failure
(BPAR, graft loss,
death or loss to
follow-up)
16 (32.7) 8 (17.0) 11 (36.7) 0.1001
Treated BPAR 13 (26.5) 6 (12.8) 5 (16.7) 0.1248
BPAR-treated
antibodies
0 (0.0) 1 (2.1) 0 (0.0) 0.4896

























49 ------------------------------------------------------- 47 CNI-WD
47 ------------------------------------------------------- 45 control
Figure 4 Kaplan–Meier estimate of probability of patient freedom
from biopsy-proven acute rejection (BPAR). Intention to treat popula-
tion, calcineurin withdrawal (CNI-WD) versus control groups.
© 2013 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT 27 (2014) 302–311 307
Chadban et al. The SOCRATES study
discontinuation of study medication in the CNI-WD
(n = 15, 31%) than in the control (n = 4, 9%) group
(P = 0.003). Twelve of the 26 events leading to study dis-
continuation in the CNI-WD group and five of seven
events in controls were considered as ‘not suspected’ in
their relationship to the study drug.
Proteinuria was an uncommonly reported adverse event
(one case only in CNI-WD and control groups); however,
among those patients who were receiving study medication
at month 12, albuminuria (ACR>3 mg/mmol) was com-
monly present [14 (64%) of CNI-WD group and 12 (38%)
of controls] although overt albuminuria (ACR>30 mg/
mmol) was present in a minority [5 (23%) of CNI-WD and
3 (9%) of controls, P = ns]. A trend towards higher rates
of anaemia (37%) and erythropoietin usage (41%) was
reported for the CNI-WD group as compared to controls
(anaemia 23%, erythropoietin usage 19%).
Similar rates of new onset diabetes after transplant (NO-
DAT) were reported for CNI-WD (32%) and control
(27%) groups, by post hoc analysis using modified Austra-
lian National Health and Medical Research Council diabe-
tes criteria to identify NODAT in patients who satisfied at
least one of the following criteria: use of glucose lowering
treatment, two fasting glucose values ≥7.0 mM or 2 random
glucose values ≥11.1 mM after day 15, or diabetes reported
as a treatment emergent adverse event.
Discussion
Steroid or Cyclosporin Removal After Transplant using
Everolimus showed that as compared to a triple immuno-
suppression control regimen of cyclosporin, mycopheno-
late and steroids, early switch to everolimus with CNI and
mycophenolate withdrawal produced noninferior eGFR at
1 year, despite incurring higher rates of BPAR and treat-
ment discontinuation. SOCRATES also demonstrated that
the use of everolimus with early steroid and mycophenolate
withdrawal was associated with an extremely high rate of
discontinuation, attributed to acute rejection, unsatisfac-
tory effect or adverse reactions.
Switch from CNI to mTOR early after transplantation
has, in other studies, been associated with significant
improvement in kidney function as compared to ongoing
CNI-based therapy [13,14]. In SOCRATES, intention to
treat analysis showed noninferior results for eGFR at month
12 but failed to show superiority. By chance, the control
group had superior week 2 eGFR, the effective baseline eGFR
as everolimus was commenced at week 2 in the CNI-WD
group. The CNI-WD group experienced a greater improve-
ment in eGFR from week 2 to month 12 as compared to con-
trols, suggesting potential benefit; however, whether this was
due to a positive effect of everolimus or simply release from
CNI-induced vasospasm was not answered by this study. As
with other switch studies [14–16], SOCRATES was charac-
terized by a high rate of withdrawal from the CNI-WD
group and those who withdrew were returned to CNI-
based therapy which may have also mitigated against
improvement in eGFR. Per-protocol analysis, undertaken
as a sensitivity analysis, demonstrated a significantly higher
mean improvement in the CNI-WD group compared with
controls, suggesting this may have been the case.
Studies of early switch from CNI- to mTOR-based ther-
apy have frequently shown an excess of acute rejection or a
trend towards more acute rejection following switch
[14–16], which was also apparent in SOCRATES. BPAR
was significantly higher in the CNI-WD group; however,
those experiencing BPAR included three patients who expe-
rienced BPAR prior to commencing everolimus and
another 11 patients, all of whom had ceased mycophenolate
and four had subtherapeutic everolimus levels according to
the protocol. As has been the case in other similar studies
[14], retaining, rather than ceasing, mycophenolate may
have substantially reduced the incidence of acute rejection
in this group. Acute rejection was more frequent among
those who did not receive basiliximab induction, again
suggesting insufficient overall immunosuppression in the
CNI-WD group.
The overall safety profile was similar to that seen in pre-
vious mTORi studies [13–21]. There were no deaths among
the everolimus-treated patients and only two cases of







Total adverse events 49 (100) 47 (100) 30 (100)
Total serious adverse events 33 (67) 31 (66) 16 (53)
Adverse events leading to study
drug discontinuation
15 (31)* 4 (9) 9 (30)
Wound complications 8 (33) 15 (32) 9 (30)
New-onset diabetes 8 (33) 13 (27) 12 (39)
Proteinuria 1 (2) 1 (2) 0 (0)
Total infections 33 (67) 34 (72) 18 (60)
CMV infection 2 (4) 4 (9) 2 (7)
Peripheral oedema 19 (39) 15 (32) 3 (10)
Diarrhoea 20 (41)* 9 (19) 5 (17)
Anaemia 18 (37) 11 (23) 9 (30)
Hypercholesterolaemia 12 (25) 9 (19) 2 (7)
Malignancy 2 (4)† 1 (2)† 0 (0)
CNI-WD = calcineurin inhibitor withdrawal group, maintained on
everolimus and prednisolone; control = control group, maintained on
cyclosporin, mycophenolate and prednisolone; steroid-WD = steroid
withdrawal group, maintained on everolimus and cyclosporin until
group was terminated by data safety monitoring board.
*P < 0.05 based on Fisher’s exact test (2-sided) CNI-WD group versus
control group. All other comparisons were not significant.
†Skin cancer (squamous or basal cell carcinoma), with no reported cases
of nonskin cancer.
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nonmelanoma skin cancer with no other malignancies
reported. Adverse events leading to drug discontinuations
were more frequent in the everolimus arms. Wound healing
events have been an issue with some studies of de novo
mTOR usage; however, SOCRATES showed no appreciable
difference between everolimus and control groups, suggest-
ing that everolimus can be safely introduced at the 2 week
point without compromising wound integrity. Anaemia
and erythropoietin usage were more common in the
CNI-WD group, despite early discontinuation of MPA.
Hyperlipidaemia was only assessed by investigator report-
ing, and no difference was seen between the CNI-WD and
control groups. Proteinuria was uncommonly reported by
investigators, and among those remaining on therapy at
month 12, the prevalence of albuminuria was not different
to controls. Consistent with other everolimus trials, the
incidence of cytomegalovirus (CMV) infection was low
[20,21].
Whether long-term improvements in patient and graft
survival can be achieved by withdrawing CNI’s remains to
be established. The ideal way to use everolimus to eliminate
or minimize the dose of CNI’s in an attempt to minimize
nephrotoxicity has yet to be found. The A2309 study
showed that everolimus with reduced dose cyclosporin
micro-emulsion had similar rates of BPAR and renal func-
tion to the CNI and MPA control group at 12 months
[21], suggesting that CNI minimization exposes patients to
additional mTORi side effects for equal efficacy. De novo
use of everolimus with basiliximab, steroids and low or very
low tacrolimus exposure has been shown to provide excel-
lent kidney function and acceptable rates of rejection and
adverse events [22,23] and is a viable alternative to switch
strategies. Early CNI elimination studies have had mixed
results in improving renal function with the trade-off being
higher rates of BPAR, study discontinuations and other
adverse events [13,17,19,24]. The ORION study [24] of
sirolimus with week 13 tacrolimus elimination or sirolimus
with mycophenolate versus a CNI-based triple therapy con-
trol, failed to show any benefit to assessed major outcomes
including BPAR, patient and graft survival. Similarly in
SOCRATES, it is possible that the failure to show improve-
ments is related to the increased rate of early BPAR in the
mTORi groups, which resulted in increased discontinua-
tions and the reintroduction of CNI and hence risk of CNI
nephrotoxicity.
Perhaps the most successful mTORi regimen is that used
in the ZEUS trial [14]. In ZEUS, patients at increased risk
of acute rejection or adverse events were excluded from
switch from cyclosporin to everolimus at 4.5 months.
ZEUS showed an improvement in mean eGFR of 9 ml/
min/1.73 m2 from the time of switch to month 12. The
control group in contrast saw a deterioration of approxi-
mately 1 ml/min/1.73 m2 over the same time period. There
are a number of important differences between the SOC-
RATES and ZEUS studies. ZEUS enrolled lower immuno-
logical risk patients, excluded those with early rejection or
other risk factors for poor outcomes after the switch,
switched to everolimus-based immunosuppression at
4.5 months after transplantation and continued switch
patients on mycophenolate.
Steroid or Cyclosporin Removal After Transplant using
Everolimus demonstrates several issues to take forward.
The trial protocol was excessively complicated for patients
and investigators alike: a simplified protocol involving an
abrupt switch from CNI to mTORi [25] will incur less risk
of complex pharmacokinetic interactions [26] and likely
better adherence and tolerance. Secondly, switch from CNI
to mTOR may be achieved with a lower risk of acute rejec-
tion at a time point later than week 2, as has been used in
other trials [14–17,25]. Exclusion of those with prior acute
rejection and those with evidence of subclinical rejection or
recurrent glomerular disease on protocol biopsy performed
prior to switch [25] may also be important to maximize the
chances of a successful switch. Finally, use of basiliximab
induction and retention of mycophenolate and steroids fol-
lowing switch may also be important in minimizing poten-
tial for acute rejection.
Steroid or Cyclosporin Removal After Transplant using
Everolimus was ultimately limited in power as only 133 of
the 177 planned patients were enrolled. This may have con-
tributed to unequal week 2 renal function. Adverse event
reporting was left to individual investigators and results
may have been skewed dependent on their familiarity with
everolimus, in that there were relatively low reports of
hyperlipidaemia and proteinuria, known everolimus side
effects. The open-label nature of the trial may have con-
tributed to the higher discontinuation rate in the everoli-
mus arms as investigators may have been more likely to
blame and discontinue patients in the active study drug
arm. Finally, use of eGFR, rather than formally measured
GFR, may have detracted from the results, particularly in
light of the relatively high number of Asian patients in the
study for whom eGFR equations are less well validated [27].
In conclusion, the 12-month results from the SOCRA-
TES show noninferiority in eGFR, but a significant excess
of acute rejection when everolimus was commenced at
week 2 to enable ultimate conversion to a double immuno-
suppressive regimen, by a progressive withdrawal of myco-
phenolate then cyclosporin in kidney transplant recipients.
Whether benefits of switch become apparent at 3 years
after transplantation will be examined.
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